adxs31-164
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02386501)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adxs31-164
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04974008 | Phase 2 | Oct 31, 2021 | George Clinical Pty Ltd, OS Therapies, Inc. |
| NCT02386501 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Advaxis, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advaxis, Inc. | For profit | 1 | 1 | 1 | 2015 |
| George Clinical Pty Ltd | Academic/Hospital | 1 | 1 | 1 | 2021 |
| OS Therapies, Inc. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1